Study of Amiloride on Vascular Phenotypes in Young Adults With Prehypertension
NCT ID: NCT01308983
Last Updated: 2012-10-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
32 participants
INTERVENTIONAL
2010-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Amiloride
Amiloride
Amiloride 10 mg orally once a day for 16 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Amiloride
Amiloride 10 mg orally once a day for 16 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female of Caucasian or African-American origin.
* No history of any major past and current medical illness (such as diabetes, renal disease, liver disease etc.)
* Not taking any medication that affects blood pressure.
Exclusion Criteria
* Serum potassium \> 5.5 mEq/L during screening and/or any testing visit due to risk of developing hyperkalemia.
* Serum creatinine \> 1.5 mg/100 ml and/or creatinine clearance \< 50 ml/min\* (Glomerular Filtration Rate Estimate by Abbreviated MDRD Study Equation)35 during screening and/or any testing visit due to risk of developing renal dysfunction.
* Female having positive pregnancy test during screening and/or any testing visit.
18 Years
35 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Augusta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yanbin Dong
Professor, Department of Pediatrics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Georgia Prevention Institute
Augusta, Georgia, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Bhagatwala J, Harris RA, Parikh SJ, Zhu H, Huang Y, Kotak I, Seigler N, Pierce GL, Egan BM, Dong Y. Epithelial sodium channel inhibition by amiloride on blood pressure and cardiovascular disease risk in young prehypertensives. J Clin Hypertens (Greenwich). 2014 Jan;16(1):47-53. doi: 10.1111/jch.12218. Epub 2013 Oct 31.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1000
Identifier Type: -
Identifier Source: org_study_id